IN2012DN06616A - - Google Patents
Info
- Publication number
- IN2012DN06616A IN2012DN06616A IN6616DEN2012A IN2012DN06616A IN 2012DN06616 A IN2012DN06616 A IN 2012DN06616A IN 6616DEN2012 A IN6616DEN2012 A IN 6616DEN2012A IN 2012DN06616 A IN2012DN06616 A IN 2012DN06616A
- Authority
- IN
- India
- Prior art keywords
- osas
- additional active
- eszopiclone
- zaleplon
- zolpidem
- Prior art date
Links
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 3
- 201000002859 sleep apnea Diseases 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 abstract 2
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 abstract 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 abstract 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 abstract 1
- 229960001578 eszopiclone Drugs 0.000 abstract 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960001165 modafinil Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960003562 phentermine Drugs 0.000 abstract 1
- 229960004010 zaleplon Drugs 0.000 abstract 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 abstract 1
- 229960001475 zolpidem Drugs 0.000 abstract 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29312910P | 2010-01-07 | 2010-01-07 | |
| PCT/US2011/020588 WO2011085256A2 (en) | 2010-01-07 | 2011-01-07 | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN06616A true IN2012DN06616A (cs) | 2015-10-23 |
Family
ID=44306177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6616DEN2012 IN2012DN06616A (cs) | 2010-01-07 | 2011-01-07 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20110224196A1 (cs) |
| EP (1) | EP2521546A4 (cs) |
| JP (1) | JP2013516488A (cs) |
| KR (1) | KR20120101588A (cs) |
| CN (1) | CN102781446A (cs) |
| AU (1) | AU2011203970A1 (cs) |
| BR (1) | BR112012016799A2 (cs) |
| CA (1) | CA2786026A1 (cs) |
| CL (1) | CL2012001844A1 (cs) |
| IL (1) | IL220552A0 (cs) |
| IN (1) | IN2012DN06616A (cs) |
| MX (1) | MX2012007813A (cs) |
| WO (1) | WO2011085256A2 (cs) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
| US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US20160045527A1 (en) * | 2014-08-14 | 2016-02-18 | Vivus, Inc. | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist |
| US20160367503A1 (en) * | 2015-06-20 | 2016-12-22 | Cary Erwin Fechter | Combination Medication for Neuro-Degenerative Diseases |
| CN108025003B (zh) * | 2015-07-08 | 2021-07-13 | 基尔罗斯制药有限公司 | 前额叶皮质处理病症，步态和肢体障碍治疗 |
| KR101961368B1 (ko) | 2016-05-11 | 2019-03-25 | 헤드너 얀 | 수면 무호흡 치료용 술티암 |
| WO2020047603A1 (en) * | 2018-09-06 | 2020-03-12 | Monash University | Method of treating a sleep breathing disorder |
| WO2021091902A1 (en) * | 2019-11-04 | 2021-05-14 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| US12046341B2 (en) | 2021-10-05 | 2024-07-23 | Bradford Rabin | Methods and systems for electronically adjusting a dosing pattern of a patient undergoing a medical regimen |
| WO2025191322A1 (en) * | 2024-03-11 | 2025-09-18 | Mousavi Mirzaei Seyed Mohammad | Therapeutic composition for improving symptoms of obstructive sleep apnea |
| WO2025207125A1 (en) * | 2024-03-26 | 2025-10-02 | The Regents Of The University Of California | Combination pharmacological interventions for obstructive sleep apnea |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021A (en) * | 1847-03-20 | Jambs haworth | ||
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2706767B1 (cs) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
| PT1158973E (pt) * | 1999-02-24 | 2005-07-29 | Univ Cincinnati | Utilizacao de derivados de sulfamato para o tratamento dos disturbios do controlo de impulsos |
| US7553818B2 (en) * | 1999-06-14 | 2009-06-30 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| US7056890B2 (en) * | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| SE0000601D0 (sv) * | 2000-02-24 | 2000-02-24 | Jan Hedner | Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet |
| FR2849029B1 (fr) * | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| US20040229943A1 (en) * | 2003-05-16 | 2004-11-18 | Cephalon Inc | Analeptic and drug combinations |
| EP1516869A1 (en) * | 2003-09-19 | 2005-03-23 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| EP2343073A3 (en) * | 2003-12-11 | 2011-10-12 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| WO2005063248A1 (en) * | 2003-12-22 | 2005-07-14 | Sepracor Inc. | Modafinil combination therapy for improving sleep quality |
| SE0400378D0 (sv) * | 2004-02-17 | 2004-02-17 | Jan Hedner | Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet |
| US20060039866A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders |
| EP1833467B1 (en) * | 2004-12-20 | 2016-08-03 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| WO2007032720A1 (en) * | 2005-09-16 | 2007-03-22 | Cereuscience Ab | Method and means of preventing and treating sleep disordered breathing |
| EP2556830A1 (en) * | 2006-12-19 | 2013-02-13 | University Of Virginia Patent Foundation | Combined effects of topiramate, ondansetron and naltrexone on alcohol consumption |
| US20100076006A1 (en) * | 2007-01-31 | 2010-03-25 | University Of Virginia Patent Foundation | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders |
| EP2455076A1 (en) * | 2007-04-09 | 2012-05-23 | Sepracor Inc. | Compositions comprising desvenlafaxine for use in treating sleep-related breathing disorders |
| EP2155664A2 (en) * | 2007-06-04 | 2010-02-24 | Generics Ýuk¨Limited | Novel process |
| US8071557B2 (en) * | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
| US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
-
2011
- 2011-01-07 WO PCT/US2011/020588 patent/WO2011085256A2/en not_active Ceased
- 2011-01-07 BR BR112012016799A patent/BR112012016799A2/pt not_active IP Right Cessation
- 2011-01-07 JP JP2012548185A patent/JP2013516488A/ja active Pending
- 2011-01-07 CN CN201180012737XA patent/CN102781446A/zh active Pending
- 2011-01-07 EP EP20110732239 patent/EP2521546A4/en not_active Ceased
- 2011-01-07 KR KR1020127020579A patent/KR20120101588A/ko not_active Withdrawn
- 2011-01-07 MX MX2012007813A patent/MX2012007813A/es unknown
- 2011-01-07 CA CA2786026A patent/CA2786026A1/en not_active Abandoned
- 2011-01-07 IN IN6616DEN2012 patent/IN2012DN06616A/en unknown
- 2011-01-07 US US12/986,921 patent/US20110224196A1/en not_active Abandoned
- 2011-01-07 AU AU2011203970A patent/AU2011203970A1/en not_active Abandoned
-
2012
- 2012-06-21 IL IL220552A patent/IL220552A0/en unknown
- 2012-07-06 CL CL2012001844A patent/CL2012001844A1/es unknown
-
2013
- 2013-10-17 US US14/056,109 patent/US20140094511A1/en not_active Abandoned
-
2015
- 2015-05-06 US US14/705,229 patent/US20150231110A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013516488A (ja) | 2013-05-13 |
| US20140094511A1 (en) | 2014-04-03 |
| EP2521546A4 (en) | 2013-06-26 |
| KR20120101588A (ko) | 2012-09-13 |
| CA2786026A1 (en) | 2011-07-14 |
| MX2012007813A (es) | 2012-08-01 |
| IL220552A0 (en) | 2012-08-30 |
| BR112012016799A2 (pt) | 2019-10-08 |
| WO2011085256A3 (en) | 2011-11-03 |
| EP2521546A2 (en) | 2012-11-14 |
| US20110224196A1 (en) | 2011-09-15 |
| AU2011203970A1 (en) | 2012-07-12 |
| US20150231110A1 (en) | 2015-08-20 |
| CN102781446A (zh) | 2012-11-14 |
| WO2011085256A2 (en) | 2011-07-14 |
| CL2012001844A1 (es) | 2013-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN06616A (cs) | ||
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| GEP20166455B (en) | Methods of administering pirfenidone therapy | |
| MY172012A (en) | Use of dpp iv inhibitors | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| WO2011041632A3 (en) | Combination therapies for the treatment of obesity | |
| ZA201209289B (en) | Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract | |
| MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| PH12012501739A1 (en) | Treatment of lupus nephritis using laquinimod | |
| NZ599928A (en) | Use of pentosan polysulfate for treatment or prophylaxis of asthma | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| NZ602478A (en) | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate | |
| WO2010151565A3 (en) | Combination therapies for the treatment of obesity | |
| NZ700824A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
| NZ576424A (en) | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor | |
| PH12013500857A1 (en) | Methods and compositions for treating hiv-associated diarrhea | |
| PH12013500559A1 (en) | Combination therapy for treating hcv infection | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| WO2010151503A3 (en) | Combination therapies for the treatment of obesity | |
| SE0400184D0 (sv) | New therapeutical use |